Profiling non-coding RNA levels with clinical classifiers in pediatric Crohn's disease.
Crohn’s disease (CD)
Differentially expressed non-coding RNAs (DE ncRNAs)
Inflammatory bowel disease (IBD)
Journal
BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628
Informations de publication
Date de publication:
29 07 2021
29 07 2021
Historique:
received:
04
10
2020
accepted:
22
07
2021
entrez:
30
7
2021
pubmed:
31
7
2021
medline:
21
1
2022
Statut:
epublish
Résumé
Crohn's disease (CD) is a heritable chronic inflammatory disorder. Non-coding RNAs (ncRNAs) play an important role in epigenetic regulation by affecting gene expression, but can also directly affect protein function, thus having a substantial impact on biological processes. We investigated whether non-coding RNAs (ncRNA) at diagnosis are dysregulated during CD at different CD locations and future disease behaviors to determine if ncRNA signatures can serve as an index to outcomes. Using subjects belonging to the RISK cohort, we analyzed ncRNA from the ileal biopsies of 345 CD and 71 non-IBD controls, and ncRNA from rectal biopsies of 329 CD and 61 non-IBD controls. Sequence alignment was done (STAR package) using Human Genome version 38 (hg38) as reference panel. The differential expression (DE) analysis was performed with EdgeR package and DE ncRNAs were identified with a threshold of fold change (FC) > 2 and FDR < 0.05 after multiple test corrections. In total, we identified 130 CD specific DE ncRNAs (89 in ileum and 41 in rectum) when compared to non-IBD controls. Similarly, 35 DE ncRNAs were identified between B1 and B2 in ileum, whereas no differences among CD disease behaviors were noticed in rectum. We also found inflammation specific ncRNAs between inflamed and non-inflamed groups in ileal biopsies. Overall, we observed that expression of mir1244-2, mir1244-3, mir1244-4, and RN7SL2 were increased during CD, regardless of disease behavior, location, or inflammatory status. Lastly, we tested ncRNA expression at baseline as potential tool to predict the disease status, disease behaviors and disease inflammation at 3-year follow up. We have identified ncRNAs that are specific to disease location, disease behavior, and disease inflammation in CD. Both ileal and rectal specific ncRNA are changing over the course of CD, specifically during the disease progression in the intestinal mucosa. Collectively, our findings show changes in ncRNA during CD and may have a clinical utility in early identification and characterization of disease progression.
Sections du résumé
BACKGROUND
Crohn's disease (CD) is a heritable chronic inflammatory disorder. Non-coding RNAs (ncRNAs) play an important role in epigenetic regulation by affecting gene expression, but can also directly affect protein function, thus having a substantial impact on biological processes. We investigated whether non-coding RNAs (ncRNA) at diagnosis are dysregulated during CD at different CD locations and future disease behaviors to determine if ncRNA signatures can serve as an index to outcomes.
METHODS
Using subjects belonging to the RISK cohort, we analyzed ncRNA from the ileal biopsies of 345 CD and 71 non-IBD controls, and ncRNA from rectal biopsies of 329 CD and 61 non-IBD controls. Sequence alignment was done (STAR package) using Human Genome version 38 (hg38) as reference panel. The differential expression (DE) analysis was performed with EdgeR package and DE ncRNAs were identified with a threshold of fold change (FC) > 2 and FDR < 0.05 after multiple test corrections.
RESULTS
In total, we identified 130 CD specific DE ncRNAs (89 in ileum and 41 in rectum) when compared to non-IBD controls. Similarly, 35 DE ncRNAs were identified between B1 and B2 in ileum, whereas no differences among CD disease behaviors were noticed in rectum. We also found inflammation specific ncRNAs between inflamed and non-inflamed groups in ileal biopsies. Overall, we observed that expression of mir1244-2, mir1244-3, mir1244-4, and RN7SL2 were increased during CD, regardless of disease behavior, location, or inflammatory status. Lastly, we tested ncRNA expression at baseline as potential tool to predict the disease status, disease behaviors and disease inflammation at 3-year follow up.
CONCLUSIONS
We have identified ncRNAs that are specific to disease location, disease behavior, and disease inflammation in CD. Both ileal and rectal specific ncRNA are changing over the course of CD, specifically during the disease progression in the intestinal mucosa. Collectively, our findings show changes in ncRNA during CD and may have a clinical utility in early identification and characterization of disease progression.
Identifiants
pubmed: 34325702
doi: 10.1186/s12920-021-01041-7
pii: 10.1186/s12920-021-01041-7
pmc: PMC8323253
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
194Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK078392
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK087694
Pays : United States
Organisme : NIDDK NIH HHS
ID : RO1-DK098231
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Life Sci. 2019 Nov 1;236:116918
pubmed: 31610208
Bioinformatics. 2011 Nov 1;27(21):3029-35
pubmed: 21930672
Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
Cell Death Dis. 2016 Aug 11;7(8):e2333
pubmed: 27512954
J Crohns Colitis. 2020 Jan 1;14(1):96-109
pubmed: 31158273
J Clin Invest. 2015 Mar 2;125(3):1363
pubmed: 25729854
Nucleic Acids Res. 2017 Jan 9;45(1):470-481
pubmed: 27899666
J Neurosci Methods. 2009 Jun 30;181(1):119-44
pubmed: 19473708
Lancet. 2017 Apr 29;389(10080):1710-1718
pubmed: 28259484
J Crohns Colitis. 2018 Feb 28;12(3):265-272
pubmed: 29506105
Am Fam Physician. 2013 May 15;87(10):699-705
pubmed: 23939448
Ann Coloproctol. 2020 Aug;36(4):243-248
pubmed: 32178500
Biochimie. 2019 Sep;164:99-104
pubmed: 30978374
Biochimie. 2004 Dec;86(12):867-74
pubmed: 15667936
BMC Bioinformatics. 2019 Jan 28;20(1):59
pubmed: 30691413
Inflamm Bowel Dis. 2019 Jan 10;25(2):235-247
pubmed: 30407525
JCI Insight. 2018 Sep 20;3(18):
pubmed: 30232290
Clin Gastroenterol Hepatol. 2021 Jun;19(6):1285-1287.e1
pubmed: 32565289
Inflamm Bowel Dis. 2018 Jan 18;24(2):346-360
pubmed: 29361088
J Crohns Colitis. 2019 Oct 28;13(11):1459-1469
pubmed: 31001642
Arq Gastroenterol. 2018 Jul-Sep;55(3):290-295
pubmed: 30540094
PLoS One. 2016 Jun 09;11(6):e0157022
pubmed: 27280887
Mol Med Rep. 2018 Jun;17(6):8189-8195
pubmed: 29693709
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W119-23
pubmed: 24838564
Curr Opin Pharmacol. 2019 Apr;45:72-80
pubmed: 31125866
Cell Mol Gastroenterol Hepatol. 2018 Aug 01;6(4):474-476.e3
pubmed: 30364773
Nucleic Acids Res. 2017 Jul 3;45(W1):W435-W439
pubmed: 28472523
Mol Med Rep. 2018 Feb;17(2):2195-2202
pubmed: 29207070
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Clin Epigenetics. 2018 Aug 8;10(1):106
pubmed: 30089516
J Gastroenterol. 2016 Jan;51(1):11-21
pubmed: 26138071
Methods Mol Biol. 2015;1284:481-501
pubmed: 25757788
J Crohns Colitis. 2020 Feb 10;14(2):267-273
pubmed: 31359034
Gastroenterology. 1998 Jul;115(1):182-205
pubmed: 9649475
Inflamm Intest Dis. 2019 Aug;4(3):97-103
pubmed: 31559261
BMC Genet. 2010 Jun 14;11:49
pubmed: 20546594
EMBO J. 1984 Dec 20;3(13):3303-10
pubmed: 6084597